Regeneron Pharmaceuticals (REGN)
558.87
+13.41 (2.46%)
NASDAQ · Last Trade: Aug 1st, 6:33 PM EDT
Shares of biotech company Regeneron (NASDAQ:REGN)
jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst expectations. The pharmaceutical giant posted earnings per share of $12.89, which crushed the forecast of $8.50. Revenue also beat projections, totaling $3.68 billion against an expected $3.29 billion. This performance marked a notable rebound from the prior quarter. The growth stemmed from strong sales of key treatments, including its eye care therapy Eylea HD, cancer drug Libtayo, and immunology medicine Dupixent, which all recorded substantial sales increases.
Via StockStory · August 1, 2025
It's a rough start to the new month for Wall Street, as major U.S. stock indices plunged by midday Friday, setting the stage for a negative weekly close.
Via Benzinga · August 1, 2025
4D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment.
Via Benzinga · August 1, 2025
Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals.
Via Benzinga · August 1, 2025
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was 52.9% above analysts’ consensus estimates.
Via StockStory · August 1, 2025
Regeneron Q2 2025 earnings beat estimates with $3.68B revenue and $12.89 EPS, but stock dips in pre-market trading. Dupixent sales surge 22% to $4.34B.
Via Chartmill · August 1, 2025
Via Benzinga · August 1, 2025
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinchstocktwits.com
Via Stocktwits · July 31, 2025
Via Benzinga · July 31, 2025
Biotech company Regeneron (NASDAQ:REGN)
will be reporting earnings this Friday before market open. Here’s what investors should know.
Via StockStory · July 30, 2025
Wall Street might be underestimating these companies' potential.
Via The Motley Fool · July 27, 2025
Via Benzinga · July 25, 2025
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Via StockStory · July 24, 2025
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Via Benzinga · July 22, 2025
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.
Via The Motley Fool · July 19, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 8.4%. This drop is a stark contrast from the S&P 500’s 5.4% gain.
Via StockStory · July 15, 2025
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
Via Benzinga · July 11, 2025
Via Benzinga · July 10, 2025
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments.
Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
Via StockStory · July 8, 2025
A U.S. bankruptcy judge ruled that California's appeal to block the deal was unlikely to succeed, rejecting claims that the sale violated state genetic privacy laws.
Via Stocktwits · July 7, 2025
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.
Via Investor's Business Daily · July 7, 2025
REGENERON PHARMACEUTICALS (NASDAQ:REGN) offers strong profitability, financial health, and an attractive valuation, making it a potential pick for value investors in the biotech sector.
Via Chartmill · July 4, 2025